Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA

Zhu, Qing; Shibata, Takayuki; Kabashima, Tsutomu; Kai, Masahiro

doi:10.1016/j.ejmech.2012.07.045

Cited by 61 publications

(52 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Zhu et al . 65 used a DNA aptamer that was converted from a reported CD4 RNA aptamer to deliver an siRNA for anti-HIV-1 protease (HIV-PR) into CD4 + T cells. The CD4 DNA aptamer was covalently conjugated to the sense strand of the siRNA to form a DNA aptamer-siRNA chimera (DAS).…”

Section: Cell-specific Aptamer-functionalized Agentsmentioning

confidence: 99%

Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy

Zhou

Rossi

2014

Molecular Therapy - Nucleic Acids

210

162

View full text Add to dashboard Cite

One hundred years ago, Dr. Paul Ehrlich popularized the “magic bullet” concept for cancer therapy in which an ideal therapeutic agent would only kill the specific tumor cells it targeted. Since then, “targeted therapy” that specifically targets the molecular defects responsible for a patient's condition has become a long-standing goal for treating human disease. However, safe and efficient drug delivery during the treatment of cancer and infectious disease remains a major challenge for clinical translation and the development of new therapies. The advent of SELEX technology has inspired many groundbreaking studies that successfully adapted cell-specific aptamers for targeted delivery of active drug substances in both in vitro and in vivo models. By covalently linking or physically functionalizing the cell-specific aptamers with therapeutic agents, such as siRNA, microRNA, chemotherapeutics or toxins, or delivery vehicles, such as organic or inorganic nanocarriers, the targeted cells and tissues can be specifically recognized and the therapeutic compounds internalized, thereby improving the local concentration of the drug and its therapeutic efficacy. Currently, many cell-type-specific aptamers have been developed that can target distinct diseases or tissues in a cell-type-specific manner. In this review, we discuss recent advances in the use of cell-specific aptamers for targeted disease therapy, as well as conjugation strategies and challenges.

show abstract

Section: Cell-specific Aptamer-functionalized Agentsmentioning

confidence: 99%

Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy

Zhou

Rossi

2014

Molecular Therapy - Nucleic Acids

210

162

View full text Add to dashboard Cite

show abstract

“…Because of their low toxicity and appropriate stability in circulating fluids, aptamers are revealing as highly promising carriers for the development of effective and safe RNA-based therapeutics. Although several recent compelling evidences have shown that interfering RNA duplexes (either siRNAs or miRNAs) [16][17][18][19][20][21][22][23] appropriately conjugated to aptamers are functionally delivered and processed into target cells in a receptor dependent manner, the use of aptamers against transmembrane receptors as carriers for therapeutic single strand antimiRs has never been addressed before. Indeed, a major hurdle of conjugating antimiR molecules to aptamers lies in the possibility that the two single chain sequences may interact each other disturbing the aptamer proper folding interfering with the specific recognition of the target receptor.…”

Section: Introductionmentioning

confidence: 99%

Selective delivery of therapeutic single strand antimiRs by aptamer-based conjugates

Catuogno

Rienzo

Vito

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

“…A number of aptamers have been developed to inhibit HIV, which are either directed to host cell receptors or viral proteins (Table 31.2), deriving a potential alternative functional cure. Aptamers against HIV RT were shown to act by competing with primer/template access, inhibiting DNA polymerization or RNase [38,39] activity [40]. When expressed in cells, viral replication was suppressed.…”

Section: Aptamers Against Hiv and Host Factorsmentioning

confidence: 99%